JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Akciju saraksts・Cassava Sciences Inc

Cassava Sciences Inc

Slēgts

SektorsVeselības aprūpe

3.81 -2.56

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.7800000000000002

Max

3.82

Galvenie mērījumi
By Trading Economics
Ienākumi	-21M -44M
Peļņas marža	-2,258.347
Darbinieki	30
EBITDA	-21M -45M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+111.64% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	104M 213M
Iepriekšējā atvēršanas cena	6.37
Iepriekšējā slēgšanas cena	3.81

Ziņu noskaņojums

By Acuity

50%

147 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

1.56 / 1.7 Atbalsts un pretestība

Cassava Sciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. okt. 18:41 UTC

Peļņas

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025. g. 24. okt. 18:31 UTC

Peļņas

Correction to Procter & Gamble to Focus on Innovation

2025. g. 24. okt. 16:25 UTC

Galvenie tirgus virzītāji

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025. g. 24. okt. 21:07 UTC

Peļņas

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025. g. 24. okt. 20:58 UTC

Peļņas

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025. g. 24. okt. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 20:40 UTC

Peļņas

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025. g. 24. okt. 20:24 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:23 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:13 UTC

Peļņas

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 20:07 UTC

Tirgus saruna

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025. g. 24. okt. 19:40 UTC

Tirgus saruna

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025. g. 24. okt. 19:35 UTC

Tirgus saruna

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025. g. 24. okt. 19:33 UTC

Peļņas

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025. g. 24. okt. 19:29 UTC

Tirgus saruna

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025. g. 24. okt. 18:52 UTC

Peļņas

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. g. 24. okt. 18:41 UTC

Peļņas

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. g. 24. okt. 18:03 UTC

Peļņas

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025. g. 24. okt. 18:02 UTC

Peļņas

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025. g. 24. okt. 18:00 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025. g. 24. okt. 16:57 UTC

Peļņas

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025. g. 24. okt. 16:54 UTC

Tirgus saruna

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025. g. 24. okt. 16:44 UTC

Tirgus saruna

Peļņas

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025. g. 24. okt. 16:39 UTC

Tirgus saruna

Peļņas

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025. g. 24. okt. 16:33 UTC

Peļņas

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 16:23 UTC

Peļņas

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 16:07 UTC

Peļņas

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Cassava Sciences Inc Prognoze

Cenas mērķis

By TipRanks

111.64% augšup

Prognoze 12 mēnešiem

Vidējais 8 USD 111.64%

Augstākais 8 USD

Zemākais 8 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cassava Sciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cassava Sciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.56 / 1.7Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

147 / 371 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.